Sponsor:

This clinical study is sponsored by Neuren Pharmaceuticals Limited, a public biopharmaceutical company developing new therapies for brain injuries, neurodevelopmental and neurodegenerative disorders. Current trials target chronic conditions such as Rett and Fragile X syndromes as well as acute neurological injuries.

For more information on Neuren Pharmaceuticals, visit www.neurenpharma.com.

The study is partially funded by Rettsyndrome.org, a 501c(3) non-profit corporation whose mission is to accelerate full spectrum research to cure Rett syndrome and empower families with knowledge and connectivity.

For more information on Rettsyndrome.org, visit www.rettsyndrome.org.